Take advantage of the uptrend.

Fundamentally, the firm’s Surperformance rating underlines the sound finances, the profitability and the consensus’ optimism. Indeed, the latter is strongly buyer (3/4 of analysts) and has set an average target price displaying an upward potential of 18%. Moreover, EPS estimates were upward revised over the past twelve months.

Edwards Lifesciences is in a bullish trend in the medium and long term. In weekly data, moving averages remain well-oriented. A recent decline brought back the securiorty in the USD 142 support area. This threshold, with the support of the rising 20-week MA, could initiate a technical rebound.

Consequently, investors may open a long position at current prices and target a reversal toward the USD 152.7 pivot point (20-day moving average). A stop loss order should be set at USD 139.85.